Treatment of Diffuse Large B Cell Lymphoma
Jae-Yong Kwak
Korean J Intern Med. 2012;27(4):369-377. Published online November 27, 2012
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in all countries and all age groups. DLBCL is potentially curable, and the outcome of patients with DLBCL has completely changed with the introduction of therapy involving the monoclonal antibody rituximab in..
|